← All Mutual Funds

FIDELITY ADVISOR SERIES VII

CIK: 0000315700 Equity
Report date: 2026-03-25
AUM $1.9B
Expense Ratio
Category Equity
State MA
Fiscal Year End
Inception Date
Manager
Latest Filing 2026-03-25

About this Fund

FIDELITY ADVISOR SERIES VII is a renowned mutual fund company that specializes in providing a wide range of investment solutions to its clients, catering to diverse financial goals and risk appetites. As a leading player in the asset management industry, the company offers a broad spectrum of mutual funds, including equity, debt, hybrid, and money market funds, among others. These funds are meticulously designed to provide investors with an opportunity to create a well-diversified portfolio, thereby minimizing risk and maximizing returns. By leveraging the expertise of seasoned investment professionals, FIDELITY ADVISOR SERIES VII employs a rigorous research-driven approach to identify lucrative investment opportunities, ensuring that its clients' wealth management needs are met with utmost precision. The company's investor-centric approach is reflected in its commitment to providing personalized investment solutions, tailored to meet the unique requirements of each client. Whether it is a seasoned investor or a novice, FIDELITY ADVISOR SERIES VII offers a comprehensive range of investment products and services, including Systematic Investment Plans (SIPs), that enable investors to achieve their long-term financial objectives. The company's robust distribution network and user-friendly online platform facilitate seamless transactions, allowing investors to easily manage their portfolios and stay abreast of market trends. With a strong focus on risk management and due diligence, FIDELITY ADVISOR SERIES VII has established itself as a trusted partner for investors seeking to navigate the complexities of the financial markets. FIDELITY ADVISOR SERIES VII's key strengths lie in its unwavering commitment to transparency, accountability, and customer satisfaction. The company's experienced team of investment managers and research analysts work in tandem to identify emerging trends and opportunities, ensuring that clients' investments are aligned with their risk profiles and financial goals. By adopting a disciplined investment approach, the company has consistently delivered strong performance across its range of mutual funds, thereby earning the trust and loyalty of its clients. As a result, FIDELITY ADVISOR SERIES VII has emerged as a preferred choice for investors seeking reliable and efficient wealth management solutions, providing them with the confidence to achieve their financial aspirations. With its rich legacy and unrelenting pursuit of excellence, the company continues to redefine the standards of asset management and investment services, solidifying its position as a leading mutual fund company in the industry.

Holdings

From latest SEC N-PORT filing · US-listed stocks only

60 positions
# Security Name CUSIP Asset Type Weight % Value ($M) Quantity
1 ORKA ORUKA THERAPEUTICS INC Since 2026-05-10 687604108 Equity (Common)
1.30%
$24.33 710,786
2 ABBV ABBVIE INC Since 2026-05-10 00287Y109 Equity (Common)
16.61%
$309.89 1,389,580
3 ALNY ALNYLAM PHARMACEUTICALS INC Since 2026-05-10 02043Q107 Equity (Common)
5.02%
$93.70 277,186
4 AMGN AMGEN INC Since 2026-05-10 031162100 Equity (Common)
2.76%
$51.52 150,703
5 RZLT REZOLUTE INC Since 2026-05-10 76200L309 Equity (Common)
0.36%
$6.63 1,985,100
6 BIIB BIOGEN INC Since 2026-05-10 09062X103 Equity (Common)
2.84%
$52.91 294,100
7 SLNO SOLENO THERAPEUTICS INC Since 2026-05-10 834203309 Equity (Common)
0.37%
$6.98 181,000
8 CLDX CELLDEX THERAPEUTICS INC Since 2026-05-10 15117B202 Equity (Common)
0.36%
$6.78 275,652
9 AVTX AVALO THERAPEUTICS INC Since 2026-05-10 05338F306 Equity (Common)
0.18%
$3.33 220,300
10 CTMX CYTOMX THERAPEUTICS INC Since 2026-05-10 23284F105 Equity (Common)
0.41%
$7.68 1,350,251
11 GILD GILEAD SCIENCES INC Since 2026-05-10 375558103 Equity (Common)
6.57%
$122.66 864,100
12 CBIO CRESCENT BIOPHARMA INC Since 2026-05-10 N/A Equity (Common)
0.13%
$2.41 251,090
13 INO INOVIO PHARMACEUTICALS INC Since 2026-05-10 45773H409 Equity (Common)
0.08%
$1.44 883,081
14 NTRA NATERA INC Since 2026-05-10 632307104 Equity (Common)
1.11%
$20.66 89,400
15 QURE UNIQURE N.V. Since 2026-05-10 N/A Equity (Common)
1.21%
$22.53 991,600
16 TVTX TRAVERE THERAPEUTICS INC Since 2026-05-10 89422G107 Equity (Common)
0.50%
$9.36 301,200
17 WVE WAVE LIFE SCIENCES LTD Since 2026-05-10 N/A Equity (Common)
0.20%
$3.75 289,700
18 VRDN VIRIDIAN THERAPEUTICS INC Since 2026-05-10 92790C104 Equity (Common)
3.15%
$58.82 1,782,464
19 TENX TENAX THERAPEUTICS INC Since 2026-05-10 88032L605 Equity (Common)
0.22%
$4.04 322,600
20 XENE XENON PHARMACEUTICALS INC Since 2026-05-10 98420N105 Equity (Common)
1.56%
$29.15 710,758
21 SYRE SPYRE THERAPEUTICS INC Since 2026-05-10 00773J202 Equity (Common)
1.28%
$23.96 749,342
22 MRNA MODERNA INC Since 2026-05-10 60770K107 Equity (Common)
1.59%
$29.72 674,300
23 ANAB ANAPTYSBIO INC Since 2026-05-10 032724106 Equity (Common)
0.38%
$7.04 148,400
24 ROIV ROIVANT SCIENCES LTD Since 2026-05-10 N/A Equity (Common)
1.13%
$21.11 976,200
25 RYTM RHYTHM PHARMACEUTICALS INC Since 2026-05-10 76243J105 Equity (Common)
0.69%
$12.94 126,200
26 XFOR X4 PHARMACEUTICALS INC Since 2026-05-10 98420X202 Equity (Common)
0.27%
$4.96 1,341,800
27 KNSA KINIKSA PHARMACEUTICALS INTERNATIONAL PLC Since 2026-05-10 N/A Equity (Common)
0.31%
$5.73 130,476
28 COGT COGENT BIOSCIENCES INC Since 2026-05-10 19240Q201 Equity (Common)
3.83%
$71.40 1,988,418
29 DNTH DIANTHUS THERAPEUTICS INC Since 2026-05-10 252828108 Equity (Common)
2.09%
$38.98 730,062
30 TECX TECTONIC THERAPEUTIC INC Since 2026-05-10 878972108 Equity (Common)
0.13%
$2.42 120,995
31 CRNX CRINETICS PHARMACEUTICALS INC Since 2026-05-10 22663K107 Equity (Common)
1.46%
$27.19 544,470
32 STOK STOKE THERAPEUTICS INC Since 2026-05-10 86150R107 Equity (Common)
0.52%
$9.64 317,700
33 ELVN ENLIVEN THERAPEUTICS INC Since 2026-05-10 29337E102 Equity (Common)
0.67%
$12.54 474,262
34 DFTX DEFINIUM THERAPEUTICS INC Since 2026-05-10 24477V105 Equity (Common)
0.13%
$2.40 141,900
35 PCVX VAXCYTE INC Since 2026-05-10 92243G108 Equity (Common)
2.29%
$42.66 796,329
36 ANNX ANNEXON INC Since 2026-05-10 03589W102 Equity (Common)
0.34%
$6.27 1,005,200
37 IRON DISC MEDICINE INC Since 2026-05-10 254604101 Equity (Common)
0.59%
$11.00 142,322
38 KYMR KYMERA THERAPEUTICS INC Since 2026-05-10 501575104 Equity (Common)
0.90%
$16.84 231,700
39 TNGX TANGO THERAPEUTICS INC Since 2026-05-10 87583X109 Equity (Common)
0.25%
$4.69 403,626
40 SMMT SUMMIT THERAPEUTICS INC Since 2026-05-10 86627T108 Equity (Common)
0.26%
$4.77 329,400
41 PRAX PRAXIS PRECISION MEDICINES INC. Since 2026-05-10 74006W207 Equity (Common)
1.45%
$27.13 86,400
42 OLMA OLEMA PHARMACEUTICALS INC Since 2026-05-10 68062P106 Equity (Common)
1.08%
$20.13 782,800
43 JBIO JADE BIOSCIENCES INC Since 2026-05-10 008064206 Equity (Common)
0.75%
$13.96 894,343
44 JANX JANUX THERAPEUTICS INC Since 2026-05-10 47103J105 Equity (Common)
0.24%
$4.39 320,385
45 NUVL NUVALENT INC Since 2026-05-10 670703107 Equity (Common)
2.27%
$42.42 412,264
46 AMLX AMYLYX PHARMACEUTICALS INC Since 2026-05-10 03237H101 Equity (Common)
1.86%
$34.77 2,433,200
47 ACLX ARCELLX INC Since 2026-05-10 03940C100 Equity (Common)
0.52%
$9.76 142,900
48 MLYS MINERALYS THERAPEUTICS INC Since 2026-05-10 603170101 Equity (Common)
0.44%
$8.24 266,800
49 ELVN ENLIVEN THERAPEUTICS INC Since 2026-05-10 N/A Equity (Common)
0.00%
739,725
50 APGE APOGEE THERAPEUTICS INC Since 2026-05-10 03770N101 Equity (Common)
1.59%
$29.65 452,639
51 RAPP RAPPORT THERAPEUTICS INC Since 2026-05-10 75383L102 Equity (Common)
0.22%
$4.18 156,946
52 CGON CG ONCOLOGY INC Since 2026-05-10 156944100 Equity (Common)
0.69%
$12.96 248,900
53 ELVN ENLIVEN THERAPEUTICS INC Since 2026-05-10 N/A Equity (Common)
0.10%
$1.94 73,200
54 ORKA ORUKA THERAPEUTICS INC Since 2026-05-10 N/A Equity (Common)
0.05%
$0.91 26,600
55 MBX MBX BIOSCIENCES INC Since 2026-05-10 55287L101 Equity (Common)
0.22%
$4.09 111,100
56 ZBIO ZENAS BIOPHARMA INC Since 2026-05-10 98937L105 Equity (Common)
0.62%
$11.56 629,316
57 UPB UPSTREAM BIO INC Since 2026-05-10 91678A107 Equity (Common)
1.15%
$21.48 691,003
58 CBIO CRESCENT BIOPHARMA INC Since 2026-05-10 N/A Equity (Common)
0.05%
$0.94 98,300
59 MAZE MAZE THERAPEUTICS INC Since 2026-05-10 578784100 Equity (Common)
0.30%
$5.58 128,000
60 ZBIO ZENAS BIOPHARMA INC Since 2026-05-10 N/A Equity (Common)
0.08%
$1.58 86,234
Frequently Asked Questions — FIDELITY ADVISOR SERIES VII
What type of mutual fund is FIDELITY ADVISOR SERIES VII?
FIDELITY ADVISOR SERIES VII is a SEC-registered Equity fund, with $1.9B in assets under management. Equity funds invest primarily in a diversified portfolio of stocks and equities, aiming for long-term capital appreciation. They carry higher market risk than bond or money market funds but historically offer stronger long-term returns. Equity mutual funds can be further classified as large-cap, mid-cap, small-cap, growth, value, or sector-specific depending on their investment mandate. As of its latest SEC N-PORT filing, FIDELITY ADVISOR SERIES VII holds 60 portfolio positions, all detailed in the holdings table on this page.
What are FIDELITY ADVISOR SERIES VII's assets under management (AUM)?
FIDELITY ADVISOR SERIES VII has $1.9B in assets under management (AUM) according to its most recent SEC N-PORT filing on StockSifting. AUM represents the total market value of all securities and other assets held by the fund as of the report date. A larger AUM generally signals a more established fund with greater institutional adoption, more trading liquidity, and potentially lower per-unit operational costs due to economies of scale. AUM changes daily as market prices fluctuate and as investors purchase or redeem fund shares — the figure shown here reflects the most recently available N-PORT disclosure, not the current real-time value. For the live figure, consult the fund's official website or its latest SEC EDGAR filing.
What are FIDELITY ADVISOR SERIES VII's top holdings?
According to FIDELITY ADVISOR SERIES VII's most recent SEC N-PORT filing, the fund's largest holdings by portfolio weight include ORUKA THERAPEUTICS INC, ABBVIE INC, ALNYLAM PHARMACEUTICALS INC , among others. The complete list of all 60 holdings — including CUSIP, asset type, portfolio weight percentage, dollar value, and share quantity — is available in the holdings table above. Holdings data is sourced directly from SEC EDGAR N-PORT filings and reflects the fund's positions as of the report date shown at the top of this page. Due to the 60-day SEC disclosure lag, these positions may differ from the fund's current portfolio. For the latest holdings before public release, refer to SEC EDGAR directly.
What is FIDELITY ADVISOR SERIES VII's expense ratio?
Expense ratio data for FIDELITY ADVISOR SERIES VII is not currently available in StockSifting's database. The expense ratio is the annual fee charged by a mutual fund as a percentage of your investment, covering management fees and operational costs. It is one of the most important factors affecting net long-term returns — lower expense ratios allow more of a fund's gross performance to flow through to investors. For the most accurate and current expense ratio, refer to the fund's official prospectus or its SEC EDGAR filings. You can also contact us if you believe this data should be present.
Where can I find FIDELITY ADVISOR SERIES VII's SEC filings?
FIDELITY ADVISOR SERIES VII is required to file monthly portfolio reports (Form N-PORT) with the U.S. Securities and Exchange Commission (SEC). Its SEC Central Index Key (CIK) is 0000315700. You can access all of FIDELITY ADVISOR SERIES VII's SEC filings — including N-PORT holdings disclosures, annual reports (Form N-CEN), and registration statements — directly on SEC EDGAR (CIK: 0000315700). N-PORT filings disclose the fund's complete portfolio holdings, fair value measurements, and certain risk metrics as of each filing period end date. StockSifting automatically parses these filings to populate the holdings table, AUM figures, and expense ratio displayed on this page, making the raw EDGAR data accessible without needing to download and parse XML files manually.
How current is FIDELITY ADVISOR SERIES VII's holdings data on StockSifting?
Holdings data for FIDELITY ADVISOR SERIES VII on StockSifting is sourced from its most recent SEC EDGAR N-PORT filing. Under SEC rules, registered investment companies must file N-PORT reports monthly, but these are made publicly available approximately 60 days after the reporting period end date. This means the holdings shown on this page reflect the fund's portfolio from roughly two months prior — not today's exact positions. The Report date displayed at the top of this page indicates exactly when the underlying data was current. If the fund has made significant portfolio changes since that date — responding to market events, earnings releases, or macro shifts — those changes will not be reflected here until the next N-PORT filing is released. For the most up-to-date holdings before the public disclosure window, refer to the fund's official website or SEC EDGAR directly. StockSifting is best used for fundamental research and historical portfolio analysis, not real-time trading decisions.